Five-by-Five: Nationwide Real-world Outcomes after ≥Five Years of Cladribine With an Age ≥50 Subanalysis (P2-20.006)

Dominika Šťastná; Marta Vachová; Jiří Drahota; Pavel Potužník; Radek Ampapa; Michal Dufek; Markéta Grünermelová; Eva Havrdová; Jana Houskova; Jana Libertínová; Alena Martinková; Zbyšek Pavelek; Marek Peterka; Eva Recmanová; Zuzana Rous; Matouš Rous; Ivana Štětkářová; Pavel Štourač; Ivana Woznicová; Dana Horakova; Gregor Fistravec

doi:10.1212/wnl.0000000000216948

Key Points

This research aims to evaluate the long-term effects of cladribine on patients with multiple sclerosis, particularly those aged 50 and above.
Nationwide analysis of real-world outcomes
Assessment of cladribine retreatment efficacy
Focus on individuals aged 50 years and older at baseline
Long-term use of cladribine demonstrated sustained efficacy in multiple sclerosis patients.
Retreatment showed favorable outcomes in the population aged 50 and above, though specific rates were not provided.

Implication

Nationally assessed long-term efficacy of cladribine in patients with multiple sclerosis, indicating insights for older populations.

Abstract

To assess long-term use of cladribine in people with multiple sclerosis (pwMS), including retreatment efficacy and observations in pwMS aged ≥50 years at baseline (first cladribine tablet) in real-world settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Šťastná et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0565c0 https://doi.org/10.1212/wnl.0000000000216948

View Full Paper

Ask AI

Bookmark

Share

Five-by-Five: Nationwide Real-world Outcomes after ≥Five Years of Cladribine With an Age ≥50 Subanalysis (P2-20.006)

Key Points

Implication

Abstract

Discussion

Cite This Study

Five-by-Five: Nationwide Real-world Outcomes after ≥Five Years of Cladribine With an Age ≥50 Subanalysis (P2-20.006)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading